journals.lww.com

Therapeutic Drug Monitoring

ORIGINAL ARTICLE: PDF Only

Department of Clinical Pharmacology, University Hospital, Tromso, Norway

*Department of Clinical Pharmacology, Huddinge University Hospital, Sweden; and †National Institute of Forensic Toxicology, Oslo, Norway

Abstract

The elimination of the muscle relaxant drug, carisoprodol, was examined in 10 healthy volunteers after an oral dose of 700 mg. In nine subjects, carisoprodol was rapidly eliminated, with a mean half-life of 99 ± 46 min, and extensively converted to meprobamate. Within 2.5 h after carisoprodol intake, meprobamate serum concentrations exceeded those of carisoprodol. Serum levels of meprobamate recorded (15–25 μmol/L) indicate that meprobamate might contribute to the effect(s) of carisoprodol. One subject eliminated carisoprodol with an overall half-life of 376 min, and only small amounts of meprobamate were recorded. This subject was found to be a poor metabolizer of mephenytoin. In spiked human sera, protein binding of carisoprodol was in the range of 41–67%, whereas meprobamate was bound to a lesser extent, 14–24%.

© Lippincott-Raven Publishers.

Full Text Access for Subscribers:

Not a Subscriber?